References
- Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity. (Abstr) Diabetes 1999; 48: 63A
- Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132(2): 118–21
- Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000; 132(2): 121–4
- Pioglitazone product information. Physicians' desk reference. 54th ed. Montvale, NJ: Medical Economics, 2000: 3088–92
- Maeda K. Hepatocellular injury in a patient receiving pioglitazone. (Letter) Ann Intern Med 2001; 135(4): 306
- Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002; 97(2): 502–3
- May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136(6): 449–52
- Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27(3): 305–13
References
- Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132(2): 118–21
- Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000; 132(2): 121–4
- Hachey DM, O'Neil MP, Force RW. Isolated elevation of alkaline phosphatase level associated with rosiglitazone. (Letter) Ann Intern Med 2000; 133(4): 752
- Ravinuthala RS, Nori U. Rosiglitazone toxicity. (Letter) Ann Intern Med 2000; 133(8): 658
- Dhawan MK, Castillo RA, Agrawal R, et al. Rosiglitazone induced granulomatous hepatitis. (Abstr) Am J Gastroenterol 2001; 96(Suppl 1): S191
- Gouda HE, Khan A, Schwartz J, et al. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001; 111(7): 584–5
- Maeda K. Hepatocellular injury in a patient receiving pioglitazone. (Letter) Ann Intern Med 2001; 135(4): 306
- Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002; 97(2): 502–3
- May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136(6): 449–52
- Avandia package insert. Philadelphia: GlaxoSmithKline, 2002
- Actos package insert. Lincolnshire, Ill: Takeda Pharmaceuticals North America, 2002
- Rezulin package insert. Secaucus, NJ: Parke-Davis, 1999
- Lebovitz HE, Salzman A. Rosiglitazone liver safety update. (Abstr) Diabetes 2000; 49(Suppl 1): A39
- Zawadski JK, Green L, Graham DJ. Thiazolidinedione-associated 15-month postmarketing hepatotoxicity. Abstract P2-567. Annual meeting of the Endocrine Society, June 2001, Denver
- Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25(5): 815–21
- Alsheikh-Ali AA, Abourjaily HM, Karas RH. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol 2002; 89(11): 1308–10
- Khan M, St Peter J, Yu D, et al. Rosiglitazone in combination with HMG-CoA reductase inhibitors does not increase the incidence of liver enzyme abnormalities in patients with type 2 diabetes. (Abstr) Diabetes 2002; 51(Suppl2): A103
- Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999; 22(12): 2067–71
- Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51(3): 797–802